PAI-1


Also found in: Acronyms.

SERPINE1

A gene on chromosome 7q21.3-q22 that encodes a serine protease inhibitor that acts on tissue plasminogen activator (tPA) and urokinase, inhibiting fibrinolysis.

Molecular pathology
SERPINE1 mutations cause plasminogen activator inhibitor-1 deficiency; high concentrations of the gene product are associated with thrombophilia.

PAI-1

Abbreviation for plasminogen activator inhibitor-1.
References in periodicals archive ?
Loureirin B was diluted with TBS buffer to different concentrations (0,12.5,25,50, and 100 [micro]M) followed by the addition of 10 [micro]L recombinant human PAI-1. After being incubated at 23[degrees]C for 15 min, uPA was added to each sample and incubated at 37[degrees] C for another 10 min.
PAI-1 is the main inhibitor in the plasminogen activation system, which comprises an inactive proenzyme (plasminogen) that can be converted into its active form the plasmin, by the action of physiological plasminogen activators; plasmin is the main enzyme that degrades fibrin into soluble products (8).
* The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1)
Real-time quantitative reverse-transcription polymerase chain reaction (RT-qPCR) was adopted to quantify the mRNA levels of KLF-4, PAI-1, and [beta]-actin with the ShinePolo One-Step RT-PCR qPCR Kit (Shanghai ShineGene Molecular Biotech, Shanghai, China) according to the kit's manual.
Co-author Dr Steven Shea added that the human circadian system causes a morning peak in circulating levels of PAI-1, independent of any behavioural or environmental influences.
Using NR8383 rat macrophages induced by LPS, we found that TNF-[alpha], IL-1[beta], TLR4, MyD88, and NF-[kappa]B levels were decreased upon PAI-1 silencing.
The aim of this study was to discover the clinicopathologic and prognostic implications of PAI-1 expression in PDAC, through improvements of aforementioned limits.
The aim of this study was dual: to assess the impact of biomarkers on the obstructive disorders of ventilation and pathophysiology of allergic asthma; and to determine the frequency of 4G/5G polymorphism in the promoter region of the PAI-1 gene in patients with asthma and compare it with control group consisting of people with no asthma and allergy symptoms.
Based on PAI-1 from a study by Ahirwar et al., 95% CI and power of 80%, using PS software for comparing mean with the ratio of (MS:COB:NC) as 1:1:1 the minimum sample size required for each group was [60.sup.13].
In epidemiological studies, direct associations were observed between PAI-1 and lipid parameters (e.g., triglyceride and HDL-C levels) in healthy young adults [12].
After blocking of endogenous peroxidase (0.5% hydrogen peroxidase in phosphate-buffered saline (PBS)) and unspecific binding (5% normal goat serum in PBS), each for 30 minutes, primary antibodies (PAI-1; Dako Denmark A/S, Glostrup, Denmark) were applied and samples were incubated at 4[degrees]C overnight.